| scholarly article | Q13442814 |
| P50 | author | Ilaria Iacobucci | Q64685191 |
| Giovanni Martinelli | Q66370881 | ||
| Pier Luigi Tazzari | Q86958213 | ||
| P2093 | author name string | James A McCubrey | |
| Annalisa Lonetti | |||
| Francesca Ricci | |||
| Alberto M Martelli | |||
| Sergio Amadori | |||
| Mirella Falconi | |||
| Andrea Ognibene | |||
| Daniela Bressanin | |||
| Francesca Chiarini | |||
| Pasqualepaolo Pagliaro | |||
| Alessandra Cappellini | |||
| Ester Orsini | |||
| Gabriella Teti | |||
| P2860 | cites work | Targeting mTOR for the treatment of AML. New agents and new directions | Q24617223 |
| Translation regulation as a therapeutic target in cancer | Q27007000 | ||
| Mechanisms of mitochondria and autophagy crosstalk | Q27011830 | ||
| Do AML patients with DNMT3A exon 23 mutations benefit from idarubicin as compared to daunorubicin? A single center experience. | Q27851686 | ||
| New and old functions of STAT3: a pivotal target for individualized treatment of cancer | Q28265930 | ||
| Inhibition of mTORC1 leads to MAPK pathway activation through a PI3K-dependent feedback loop in human cancer | Q29618030 | ||
| Clofarabine in leukemia | Q34150263 | ||
| Targeting the translational apparatus to improve leukemia therapy: roles of the PI3K/PTEN/Akt/mTOR pathway | Q34173253 | ||
| Two hits are better than one: targeting both phosphatidylinositol 3-kinase and mammalian target of rapamycin as a therapeutic strategy for acute leukemia treatment. | Q34260622 | ||
| The role of clofarabine in acute myeloid leukemia | Q34298181 | ||
| Age and acute myeloid leukemia | Q34564663 | ||
| Stat3 signaling in acute myeloid leukemia: ligand-dependent and -independent activation and induction of apoptosis by a novel small-molecule Stat3 inhibitor | Q35030931 | ||
| The R(h)oads to Stat3: Stat3 activation by the Rho GTPases | Q35086590 | ||
| Autophagy in the pathogenesis of myelodysplastic syndrome and acute myeloid leukemia. | Q35124582 | ||
| FLIP regulation of HO-1 and TNF signalling in human acute myeloid leukemia provides a unique secondary anti-apoptotic mechanism | Q35169597 | ||
| Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells | Q35556981 | ||
| Protection of acute myeloid leukaemia cells from apoptosis induced by front-line chemotherapeutics is mediated by haem oxygenase-1 | Q35640339 | ||
| Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health | Q35679353 | ||
| Regulation of macroautophagy in ovarian cancer cells in vitro and in vivo by controlling glucose regulatory protein 78 and AMPK. | Q36050696 | ||
| Activation of the PTEN/mTOR/STAT3 pathway in breast cancer stem-like cells is required for viability and maintenance | Q36092560 | ||
| Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels | Q36339232 | ||
| Signal transducer and activator of transcription 3 is required for abnormal proliferation and survival of TSC2-deficient cells: relevance to pulmonary lymphangioleiomyomatosis. | Q37402798 | ||
| MYC as a regulator of ribosome biogenesis and protein synthesis | Q37718002 | ||
| Perspectives on inhibiting mTOR as a future treatment strategy for hematological malignancies | Q37779489 | ||
| Roles of the Ras/Raf/MEK/ERK pathway in leukemia therapy. | Q37865381 | ||
| Clonal evolution of acute leukemia genomes | Q37986426 | ||
| Clofarabine in pediatric acute leukemia: current findings and issues | Q37987061 | ||
| Novel and emerging drugs for acute myeloid leukemia | Q38000711 | ||
| The JAK-STAT pathway at twenty | Q38004201 | ||
| Acute myelogenous leukemia stem cells: from Bench to Bedside. | Q38020081 | ||
| Remission induction in acute myeloid leukemia | Q38026006 | ||
| Identifying leukemia stem cells--is it feasible and does it matter? | Q38028260 | ||
| Current treatment of acute myeloid leukemia | Q38046723 | ||
| Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a | Q39328413 | ||
| Cytotoxic activity of the novel Akt inhibitor, MK-2206, in T-cell acute lymphoblastic leukemia. | Q39344848 | ||
| Autophagy is required for the activation of NFκB. | Q39424847 | ||
| Mutant p53 oncogenic functions are sustained by Plk2 kinase through an autoregulatory feedback loop. | Q39434450 | ||
| AMP-dependent kinase/mammalian target of rapamycin complex 1 signaling in T-cell acute lymphoblastic leukemia: therapeutic implications. | Q39463725 | ||
| Targeted inhibition of mTORC1 and mTORC2 by active-site mTOR inhibitors has cytotoxic effects in T-cell acute lymphoblastic leukemia. | Q39590044 | ||
| Targeting of active mTOR inhibits primary leukemia T cells and synergizes with cytotoxic drugs and signaling inhibitors | Q39600915 | ||
| Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. | Q39650704 | ||
| Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. | Q39653305 | ||
| Mechanisms of the apoptotic activity of Cl-F-araA in a human T-ALL cell line, CCRF-CEM. | Q40707620 | ||
| Treatment of acute myeloid leukemia | Q41893399 | ||
| Oct1 is required for mTOR-induced G1 cell cycle arrest via the control of p27(Kip1) expression | Q42863180 | ||
| Chemical genomic screening reveals synergism between parthenolide and inhibitors of the PI-3 kinase and mTOR pathways | Q42871137 | ||
| Deoxyadenosine analogs induce programmed cell death in chronic lymphocytic leukemia cells by damaging the DNA and by directly affecting the mitochondria. | Q43741513 | ||
| Protein synthesis is resistant to rapamycin and constitutes a promising therapeutic target in acute myeloid leukemia. | Q46003222 | ||
| The dual mTORC1 and mTORC2 inhibitor AZD8055 has anti-tumor activity in acute myeloid leukemia. | Q50506558 | ||
| Rapamycin inhibits both motility through down-regulation of p-STAT3 (S727) by disrupting the mTORC2 assembly and peritoneal dissemination in sarcomatoid cholangiocarcinoma. | Q52628427 | ||
| Mammalian target of rapamycin (mTOR) inhibition activates phosphatidylinositol 3-kinase/Akt by up-regulating insulin-like growth factor-1 receptor signaling in acute myeloid leukemia: rationale for therapeutic inhibition of both pathways. | Q53526869 | ||
| Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107) | Q82498689 | ||
| Novel agents in acute myeloid leukemia | Q84831447 | ||
| P433 | issue | 12 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | leukemia | Q29496 |
| acute myeloid leukemia | Q264118 | ||
| allosteric inhibitor | Q70361704 | ||
| P304 | page(s) | 1615-1628 | |
| P577 | publication date | 2012-12-01 | |
| P1433 | published in | Oncotarget | Q1573155 |
| P1476 | title | A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia | |
| P478 | volume | 3 |
| Q92326780 | A Phase 1B Clinical Study of Combretastatin A1 Diphosphate (OXi4503) and Cytarabine (ARA-C) in Combination (OXA) for Patients with Relapsed or Refractory Acute Myeloid Leukemia |
| Q39107105 | A hidden role of the inactivated FANCD2: upregulating ΔNp63. |
| Q38949674 | Activity of the novel mTOR inhibitor Torin-2 in B-precursor acute lymphoblastic leukemia and its therapeutic potential to prevent Akt reactivation |
| Q27686983 | Advances in targeting signal transduction pathways |
| Q26744536 | Anti-Cancer Stem-like Cell Compounds in Clinical Development - An Overview and Critical Appraisal |
| Q34365926 | Assessment of the effect of sphingosine kinase inhibitors on apoptosis,unfolded protein response and autophagy of T-cell acute lymphoblastic leukemia cells; indications for novel therapeutics |
| Q36546701 | Auranofin induces apoptosis by ROS-mediated ER stress and mitochondrial dysfunction and displayed synergistic lethality with piperlongumine in gastric cancer |
| Q26828544 | Autophagy in acute leukemias: a double-edged sword with important therapeutic implications |
| Q39147611 | Carnosine Inhibits the Proliferation of Human Gastric Carcinoma Cells by Retarding Akt/mTOR/p70S6K Signaling. |
| Q39158015 | Cell death sensitization of leukemia cells by opioid receptor activation |
| Q36299762 | Circulating and tumor-infiltrating Tim-3 in patients with colorectal cancer |
| Q34103963 | Deregulation of the EGFR/PI3K/PTEN/Akt/mTORC1 pathway in breast cancer: possibilities for therapeutic intervention |
| Q42541266 | Enhancing the effectiveness of nucleoside analogs with mTORC1 blockers to treat acute myeloid leukemia patients |
| Q27013811 | GSK-3 as potential target for therapeutic intervention in cancer |
| Q35854097 | Glycyrrhizic acid inhibits leukemia cell growth and migration via blocking AKT/mTOR/STAT3 signaling |
| Q42505783 | Immunosuppressants in cancer prevention and therapy |
| Q37360025 | Improving nelarabine efficacy in T cell acute lymphoblastic leukemia by targeting aberrant PI3K/AKT/mTOR signaling pathway |
| Q37589123 | Induction of apoptosis by directing oncogenic Bcr-Abl into the nucleus |
| Q36292001 | Koschei the immortal and anti-aging drugs |
| Q52846906 | Novel strategies for targeting leukemia stem cells: sounding the death knell for blood cancer. |
| Q37132224 | Pharmacological targeting of the PI3K/mTOR pathway alters the release of angioregulatory mediators both from primary human acute myeloid leukemia cells and their neighboring stromal cells |
| Q37132233 | Potent antitumor activity of oncolytic adenovirus expressing Beclin-1 via induction of autophagic cell death in leukemia |
| Q37228766 | Rapamycin extends life- and health span because it slows aging |
| Q34392470 | Selective anti-cancer agents as anti-aging drugs |
| Q34365708 | Selenocysteine derivative overcomes TRAIL resistance in melanoma cells: evidence for ROS-dependent synergism and signaling crosstalk |
| Q35824678 | Strategy to enhance efficacy of doxorubicin in solid tumor cells by methyl-β-cyclodextrin: Involvement of p53 and Fas receptor ligand complex |
| Q33757127 | Strategy to enhance the therapeutic effect of doxorubicin in human hepatocellular carcinoma by selenocystine, a synergistic agent that regulates the ROS-mediated signaling |
| Q37306916 | Synergistic antitumor activity of rapamycin and EF24 via increasing ROS for the treatment of gastric cancer. |
| Q41904096 | Synergistic effects of selective inhibitors targeting the PI3K/AKT/mTOR pathway or NUP214-ABL1 fusion protein in human Acute Lymphoblastic Leukemia |
| Q33608493 | Targeting MYC Dependence by Metabolic Inhibitors in Cancer |
| Q47110143 | Targeting signaling and apoptotic pathways involved in chemotherapeutic drug-resistance of hematopoietic cells |
| Q38790630 | Targeting the mTOR Pathway in Leukemia |
| Q39096231 | Temsirolimus improves cytotoxic efficacy of cisplatin and gemcitabine against urinary bladder cancer cell lines. |
| Q37299276 | The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy |
| Q38924436 | The interplay of autophagy and β-Catenin signaling regulates differentiation in acute myeloid leukemia |
| Q38871688 | The novel dual PI3K/mTOR inhibitor NVP-BGT226 displays cytotoxic activity in both normoxic and hypoxic hepatocarcinoma cells |
| Q33952803 | Therapeutic targeting of Polo-like kinase-1 and Aurora kinases in T-cell acute lymphoblastic leukemia |
| Q42440865 | Triple Akt inhibition as a new therapeutic strategy in T-cell acute lymphoblastic leukemia |
| Q37616010 | Understanding of leukemic stem cells and their clinical implications. |
| Q38737064 | mTOR inhibitors in urinary bladder cancer. |
Search more.